Next-generation pneumococcal vaccine development
Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing multiple antigens to be incorporated in a single vaccine.
-
Domain
-
Investment typeDirect equity
-
StatusExit
-
Initial investmentSeries A
-
Partnered in2014
-
Investment leadDavid Rossow
-
HeadquartersUSA
-
Program strategyPneumonia
Portfolio news
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.